Lovastatin Tablet
Product Images NDC 63629-1018

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lovastatin (NDC 63629-1018). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl636291018)

Lovastatin Tablets, USP 10 mg oral tablets label with NDC 63629-1018-1. The label includes dosage strength in a highlighted box, barcodes, and manufacturer information from Carlsbad Technology, Inc., repackaged by Bryant Ranch Prepack. It indicates a package size of 100 tablets and is marked Rx only. The BRP Pharmaceuticals logo is also visible.*

FDA Label Image

Structural Formula (Lov00 0004 01)

Chemical structure of Lovastatin, showing its molecular arrangement with multiple rings and functional groups, consistent with the Lovastatin active ingredient.*

FDA Label Image

Table I (Lov00 0004 02)

A data table titled 'The Effect of Other Drugs on Lovastatin Exposure When Both Were Co-administered.' It lists drugs or grapefruit juice, dosing regimens, lovastatin dosing, number of subjects, and AUC ratios indicating exposure changes to lovastatin when co-administered with these agents. Drugs include Gemfibrozil, Itraconazole, Grapefruit juice (high and low dose), Cyclosporine, and Diltiazem.*

FDA Label Image

Figure 1 (Lov00 0004 03)

A line graph labeled 'Figure 1 Acute Major Coronary Events (Primary Endpoint)' shows the proportion of participants without event over six years of follow-up. Two lines represent Lovastatin and placebo groups, indicating a 37% risk reduction with Lovastatin (p < 0.001). The x-axis denotes years of follow-up (0 to 6), and the y-axis ranges from 0.90 to 1.0 for the proportion without event.*

FDA Label Image

Table Vii (Lov00 0005 04)

A table titled 'Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis' listing interacting agents such as strong CYP3A4 inhibitors, HIV protease inhibitors, and others, along with specific prescribing recommendations for lovastatin, including contraindications and dosage limits.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.